Advertisement
Screener

Allarity Therapeutics, Inc. (ALLR) Deferred Offering Costs

2.8 / 5 stars · 68/120 Roast Me

Allarity Therapeutics, Inc. Deferred Offering Costs

Allarity Therapeutics, Inc. (ALLR) had Deferred Offering Costs of $3.35 million as of 2023-04-20, per its 10-K filed 2024-03-08.

Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current

us-gaap:DeferredOfferingCosts · last filed 2024-03-08

  • 2023-04-20: Deferred Offering Costs $3.35M.
  • 2023-03-31: Deferred Offering Costs $150.00K.
Period endDeferred Offering Costs
2023-04-20$3.35M
10-K · filed 2024-03-08
2023-03-31$150.00K
10-Q · filed 2023-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B